Intraneoplastic Administration of Bleomycin in Intracerebral Gliomas: A Pilot Study

  • D. A. Bosch
  • Th. Hindmarsch
  • St. Larsson
  • E.-O. Backlund
Part of the Acta Neurochirurgica Supplementum book series (NEUROCHIRURGICA, volume 30)


As human malignant gliomas of the brain cannot be treated successfully by conventional means, i.e., bulk resection + radiotherapy, eventually combined with the systemic administration of cytostatic agents, we decided to start a trial consisting of stereotactic biopsy of the tumour and placement of a small catheter in the center of the tumour to administer chemotherapeutic agents. In contrast with those agents used in systemic administration that should be of small molecular size and lipid soluble to penetrate the CNS, for intraneoplastic drug delivery drugs could be used that do not pass the blood brain barrier. It seemed reasonable to chose a drug that will neither pass this barrier nor the brain-blood barrier. Besides that the drug should be a non-cell cycle specific drug as gliomas have a very low growth fraction 5 and should have shown at least some effectivity against glioma cells both in vivo and in vitro 7-9. Bleomycin fulfilled all these criteria 2, 6 and has been taken as the first agent to test in this way.


Glioma Cell Malignant Glioma Cytosine Arabinoside Stereotactic Biopsy Cytostatic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ausman, J. I., Levin, V. A., Brown, W. E., Rall, D. P., Fenstermacher, J. D., Brain-tumor chemotherapy. J. Neurosurg. 46 (1977), 155–164.PubMedCrossRefGoogle Scholar
  2. 2.
    Barranco, S. C., Bolton, W. E., Cell cycle phase recovery from Bleomycin- induced potentially lethal damage. Cancer Res. 37 (1977), 2589–2591.PubMedGoogle Scholar
  3. 3.
    Blasberg, R. G., Patlak, C., Fenstermacher, J. D., Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther.195 (1975), 73.PubMedGoogle Scholar
  4. 4.
    Blasberg, R. G., Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat. Rep. 61 (1977), 625–631.PubMedGoogle Scholar
  5. 5.
    Fewer, D., Wilson, Ch. B., Levin, V. A., Brain tumor chemotherapy. Springfield, Ill.: Ch. C Thomas. 1976.Google Scholar
  6. 6.
    Hahn, G. M., Gordon, L. F., Kurkjian, S. D., Responses of cycling and non- cycling cells to 1.3-Bis(2-chloroethyl)-1-nitrosourea and to Bleomycin. Cancer Res.34 (1974), 2373–2377.PubMedGoogle Scholar
  7. 7.
    Hayakawa, T., Ushio, Y., Mogami, H., Horibata, K., The uptake, distribution and anti-tumor activity of Bleomycin in gliomas in the mouse. Europ. J. Cancer 10 (1974), 137–142.CrossRefGoogle Scholar
  8. 8.
    Hayakawa, T., Ushio, Y., Morimoto, K., Hasegawa, H., Mogami, H., Horibata, K., Uptake of Bleomycin by human brain tumours. J. Neurol., Neurosurg. Psychiat. 39 (1976), 341–349.CrossRefGoogle Scholar
  9. 9.
    Takeuchi, K., A clinical trial of intravenous Bleomycin in the treatment of brain tumors. Int. J. Clin. Pharmacol. 12 (1975), 419–426.Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • D. A. Bosch
    • 1
  • Th. Hindmarsch
    • 2
  • St. Larsson
    • 2
  • E.-O. Backlund
    • 2
  1. 1.Department of NeurosurgeryUniversity HospitalGroningenThe Netherlands
  2. 2.Department of NeurosurgeryKarolinska SjukhusStockholmSweden

Personalised recommendations